|
|
Enron Mail |
Mime-Version: 1.0
Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-From: subscriptions@stockscape.com@ENRON <IMCEANOTES-subscriptions+40stockscape+2Ecom+40ENRON@ENRON.com< X-To: alewis@ect.enron.com X-cc: X-bcc: X-Folder: \Lewis, Andrew H.\Lewis, Andrew H.\Deleted Items X-Origin: LEWIS-A X-FileName: Lewis, Andrew H..pst Andrew, This free service is brought to you by Stockscape.com ( http://www.stockscape.com ) THE FAGAN REPORT / http://www.faganreport.com OPT-IN EMAIL SERVICE TRADE ALERT #13 CEPHEID / (Nasdaq - CPHD) May 31, 2001 09:45AMET - emailed to TFR Trade Alert Subscribers NOTE - DELAYED DELIVERY: This information was previously distributed to Fagan Report Trade Alert Subscribers at the above noted time and date. Due to ever-changing market considerations - it may or may not be applicable at this time. TRADE ALERT #13 - Speculative Buy / Cepheid / (Nasdaq - CPHD), currently trading at $3.50 with a target above $6.00 and a stop-loss at $2.89. Cepheid (CPHD), based in Sunnyvale, CA, is developing and commercializing versatile, miniaturized instruments that perform all the steps required to rapidly analyze genetic material found in complex biological samples -- sample preparation, amplification, and detection. Integrating proprietary microfluidic and microelectronic technologies. It is commercializing products initially for DNA and RNA analysis in clinical diagnostics, life-science research, agriculture, industrial testing, and pharmacogenetics. Not many stock speculators can decipher the above paragraph, but if you go to www.cepheid.com it all begins to make sense. Cepheid is making it possible to do complicated, critical compound analysis on site in vastly reduced time frames. The range of applications is almost unlimited. It can help detect the spread of cancerous cells during a surgical procedure. In agriculture, it is being tested to identify the spread of Pierce Disease in the California grapevine industry. I looked up Pierce Disease and found the following: Pierce's disease infects grapevines, effectively choking the tissues that deliver water and nutrients throughout the plant. Infected ines usually die within a few years. The disease has been present in California at relatively low levels for decades, but is cause for heightened concern because the glassy-winged sharpshooter (insect), newly arrived from the southeastern U.S. and northern Mexico, can spread it much more rapidly than native insects. - SACRAMENTO, Calif., May 16, 2001 /PRNewswire via COMTEX/ -- Cepheid (Nasdaq: CPHD) today announced that its Smart Cycler(R) TD System is being exhibited for early detection of Pierce's disease in grape vines at today's 13th annual California Association of Professional Scientists (CAPS) State Scientists Day held at the Capitol. Using the portable, real-time gene-detection system, for the first time scientists can detect the lethal disease before symptoms appear, allowing vintners to remove infected vines earlier in the growing season before the disease is spread by insect carriers. Situations like this have the potential to catch the imagination of the market. CPHD went public in June 2000 through an IPO (led by VSB Warburg) of five million shares at $6.00. A further 20.5 million pre-IPO issued shares became free trading in December 2000. Presently, there are 25.5 million shares issued. As of March 31, 2001, cash on hand stood at $37 million - current liabilities $5 million. Based on published information, I estimate FY01 revenue of between $15 and $20 million, with a net cash burn of $12-$18 million. FY02 is where sales and profits should start to improve. CPHD's 52-week high/low stock price is $27.50 / $2.97. What I like about CPHD is its cutting-edge technology in what is likely to be an in-vogue market sector. NOTE / DISCLAIMER All information published by The Fagan Report is for informational purposes only. As Editor, I, Brian Fagan, tell you what I am or would be doing if I had sufficient capital to do so. You read and/or subscribe to receive this information for whatever personal reasons you may have to do so. Nothing more is implied or intended. Nothing in this communication is, nor should it be construed to be an offer or solicitation for the purchase or sale of securities. Please see our complete disclaimer statement at: http://www.faganreport.com COPYRIGHT: Fagan Report Trade Alerts are copyright material. It is unlawful to duplicate, forward, or disseminate this information in any form whatsoever, without the written permission of the publisher. For copyright waiver, email your request to: info@faganreport.com . Wishing you all the best, The Fagan Report, Brian Fagan ********************************************************************** THE FAGAN REPORT OPT-IN EMAIL SERVICE May 31, 2001 You have received this information because you have previously subscribed to The Fagan Report complimentary opt-in email service at http://www.faganreport.com . Through your participation in this program, you receive all information sent to paying subscribers of The Fagan Report, but on a variable time-delayed basis. This is an "OPT-IN" email service, the cost of which is borne in part by company sponsors. Today's content is independent research, opinions, and commentary. It is not company sponsored. No compensation of any kind has been paid or received for its inclusion in The Fagan Report. ---------------------------------------------------------------- The information being sent to you is intended as a free, value-added service. If you wish to unsubscribe to this publication please go to the following page and enter your e-mail address: http://www.stockscape.com/stockscape_com/unsubscribe/ChangeSubscriptions.cfm (If you are an AOL user and you wish to unsubscribe to this publication, please <a href="http://www.stockscape.com/stockscape_com/unsubscribe/ChangeSubscriptions.cfm"<click here</a<) Please be aware that Stockscape is a news service and NOT an investment advisory service, it is recommended that you consult with a licensed financial advisor before making any investment decisions. The information herein should NOT be construed as an offer to buy or sell securities. The information is taken from sources thought to be accurate but there is 0 guarantee. All due diligence should be done by the reader or their financial advisor.
|